Liprostin™

Liprostin is the liposome-encapsulated form of prostaglandin E-1 (PGE-1). A naturally occurring hormone, prostaglandin E-1 has been shown to be a potent vasodilator and platelet inhibitor, as well as an anti-inflammatory and anti-thrombotic agent. In 1983, the U.S. Food and Drug Administration (FDA) approved prostaglandin E-1 for the treatment of ductus arteriosis of Botalli in neonates. Thus, much of the preclinical and clinical development and toxicology regarding the drug itself is known.

The liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve. Liprostin has the potential to positively impact many areas of treatment, including:

• Peripheral Arterial Occlusive Disease (Critical Limb
        Ischemia or Intermittent Claudication)
• Post-myocardial infarction therapy
• Ischemic ulcers
• Critical limb salvage
• Claudicants
• Pulmonary Hypertension
• Diabetic neuropathy
• Arthritis

MARKET POTENTIAL

At the very least, Endovasc believes Liprostin can potentially improve quality of life for the 10 to 12 million Americans who suffer from peripheral arterial occlusive disease (PAOD) also referred to as peripheral artery disease (PAD).  Endovasc intends to seek the efficacy for the other indications listed above which represent a significant market potential.
 

Click here to view Liprostin Clinical Trials.